Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

Ayisha Sharma

News Reporter

Sanofi posted a strong set of first-quarter results Thursday morning, with its recombinant factor drug Altuviiio on track to become a blockbuster drug and its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche CEO warns that tariffs could impact dealmaking

Bristol Myers' transition moves forward as it raises 2025 revenue forecast

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

Merck’s Gardasil sales sink further amid China market pressure

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Sanofi's Al­tuvi­i­io clos­ing in on block­buster sta­tus, Dupix­ent sales surge

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge